我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
31
3 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
1
3.2%
已完成
18
58.1%
尚未招募
2
6.5%
招募中
9
29.0%
暂停
暂无批准数据
- A Japanese real-world study of 18 patients with diabetic macular edema demonstrated that faricimab significantly improved central macular thickness in both treatment-naïve and treatment-switched patients. - Treatment-naïve patients showed significant visual acuity improvements (p=0.03), while patients switched from other anti-VEGF therapies maintained stable vision with anatomical improvements. - The study validates faricimab's clinical effectiveness under flexible dosing regimens, with patients receiving an average of 3.3 injections over 6.3 months of follow-up. - Results support faricimab's dual VEGF-A and Ang2 inhibition mechanism as an effective treatment option for diabetic macular edema in real-world clinical practice.
